Overview

Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well lapatinib ditosylate works in treating patients with unresectable liver or biliary tract cancer
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Lapatinib